Verano (VRNO) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
18 Jun, 2026Opening remarks and agenda
Meeting called to order by the Chairman, who welcomed attendees and introduced the Chief Investment Officer to outline the meeting's conduct.
Rules for virtual participation, voting eligibility, and meeting procedures were explained, including electronic ballot instructions and technical contingency plans.
Attendees were informed about the process for submitting questions and the roles of key officers and the Inspector of Elections.
Confirmation of quorum and proper distribution of meeting materials was provided.
Board and executive committee updates
Five current directors were nominated for re-election to serve until the next annual meeting or until successors are appointed.
Shareholder proposals
Four proposals were presented: election of directors, advisory approval of executive compensation, ratification of the independent auditor, and re-approval of the stock and incentive plan.
Latest events from Verano
- Regulatory shifts and market expansions in key states are set to drive double-digit growth.VRNO
Canaccord Genuity's 46th Annual Growth Conference - Q2 2026 revenue hit $218M, with 46% gross margin and $20M share repurchase amid federal reform.VRNO
Q2 2026 - Q1 2026 revenue reached $208.2M, with retail gains and a $20M share repurchase announced.VRNO
Q1 2026 - 2025 revenue reached $822M with margin gains, new financing, and national retail expansion.VRNO
Q4 2025 - Q3 revenue hit $203M, margins held, net loss widened, and new credit and retail expansion drive outlook.VRNO
Q3 2025 - Q2 revenue reached $222.4M, with wholesale gains and expansion into Virginia, Arizona, and Ohio.VRNO
Q2 2024 - All AGM proposals passed, with annual advisory votes on executive pay and five directors elected.VRNO
AGM 2024 - Q1 2025 revenue fell 5% to $210M, with margins down and net loss widening to $12M.VRNO
Q1 2025 - 2024 revenue hit $879M with strong wholesale gains, but asset impairments drove a $342M net loss.VRNO
Q4 2024